Both low expression and nuclear retention of MBNL1 play an adverse role in the pathogenesis of DM1; therefore, reducing or eliminating the nuclear retention of MBNL1 could be another effective treatment for DM113,39. Here, MBNL1 is linked to myotonic dystrophy type 1.